These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 28588262

  • 1. Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain.
    Qiu HY, Zhu X, Luo YL, Lin HY, Tang CY, Qi JL, Pang YJ, Yang RW, Lu GH, Wang XM, Yang YH.
    Sci Rep; 2017 Jun 06; 7(1):2863. PubMed ID: 28588262
    [Abstract] [Full Text] [Related]

  • 2. Identification of new shikonin derivatives as STAT3 inhibitors.
    Qiu HY, Fu JY, Yang MK, Han HW, Wang PF, Zhang YH, Lin HY, Tang CY, Qi JL, Yang RW, Wang XM, Zhu HL, Yang YH.
    Biochem Pharmacol; 2017 Dec 15; 146():74-86. PubMed ID: 29066190
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition.
    Li N, Ou J, Bao N, Chen C, Shi Z, Chen L, Sun J.
    Bioorg Chem; 2020 Nov 15; 104():104208. PubMed ID: 32919131
    [Abstract] [Full Text] [Related]

  • 4. Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy.
    Zhang W, Guo J, Li S, Ma T, Xu D, Han C, Liu F, Yu W, Kong L.
    Sci Rep; 2017 Apr 11; 7():46352. PubMed ID: 28397855
    [Abstract] [Full Text] [Related]

  • 5. Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors.
    Gao D, Jin N, Fu Y, Zhu Y, Wang Y, Wang T, Chen Y, Zhang M, Xiao Q, Huang M, Li Y.
    Eur J Med Chem; 2021 Apr 15; 216():113333. PubMed ID: 33689932
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy.
    Feng KR, Wang F, Shi XW, Tan YX, Zhao JY, Zhang JW, Li QH, Lin GQ, Gao D, Tian P.
    Eur J Med Chem; 2020 Sep 01; 201():112428. PubMed ID: 32603980
    [Abstract] [Full Text] [Related]

  • 7. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
    Löcken H, Clamor C, Müller K.
    J Nat Prod; 2018 Jul 27; 81(7):1636-1644. PubMed ID: 30003778
    [Abstract] [Full Text] [Related]

  • 8. Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth.
    Li X, Ma H, Li L, Chen Y, Sun X, Dong Z, Liu JY, Zhu W, Zhang JT.
    Oncogene; 2018 May 27; 37(18):2469-2480. PubMed ID: 29456240
    [Abstract] [Full Text] [Related]

  • 9. Identification of novel STAT3 inhibitors bearing 2-acetyl-7-phenylamino benzofuran scaffold for antitumour study.
    Wang F, Feng KR, Zhao JY, Zhang JW, Shi XW, Zhou J, Gao D, Lin GQ, Tian P.
    Bioorg Med Chem; 2020 Dec 15; 28(24):115822. PubMed ID: 33126089
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3.
    Wang X, He Q, Wu K, Guo T, Du X, Zhang H, Fang L, Zheng N, Zhang Q, Ye F.
    Eur J Med Chem; 2019 Oct 01; 179():218-232. PubMed ID: 31254923
    [Abstract] [Full Text] [Related]

  • 11. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).
    Li C, Chen C, An Q, Yang T, Sang Z, Yang Y, Ju Y, Tong A, Luo Y.
    Eur J Med Chem; 2019 Jan 15; 162():543-554. PubMed ID: 30472602
    [Abstract] [Full Text] [Related]

  • 12. Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain.
    Page BD, Fletcher S, Yue P, Li Z, Zhang X, Sharmeen S, Datti A, Wrana JL, Trudel S, Schimmer AD, Turkson J, Gunning PT.
    Bioorg Med Chem Lett; 2011 Sep 15; 21(18):5605-9. PubMed ID: 21788134
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis and biological evaluation of anilide (dicarboxylic acid) shikonin esters as antitumor agents through targeting PI3K/Akt/mTOR signaling pathway.
    Ma Y, Yang X, Han H, Wen Z, Yang M, Zhang Y, Fu J, Wang X, Yin T, Lu G, Qi J, Lin H, Wang X, Yang Y.
    Bioorg Chem; 2021 Jun 15; 111():104872. PubMed ID: 33838560
    [Abstract] [Full Text] [Related]

  • 14. Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors.
    Cai G, Yu W, Song D, Zhang W, Guo J, Zhu J, Ren Y, Kong L.
    Eur J Med Chem; 2019 Jul 15; 174():236-251. PubMed ID: 31048139
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701.
    Nishisaka F, Taniguchi K, Tsugane M, Hirata G, Takagi A, Asakawa N, Kurita A, Takahashi H, Ogo N, Shishido Y, Asai A.
    Cancer Sci; 2020 May 15; 111(5):1774-1784. PubMed ID: 32112605
    [Abstract] [Full Text] [Related]

  • 16. 4-Carbonyl-2,6-dibenzylidenecyclohexanone derivatives as small molecule inhibitors of STAT3 signaling pathway.
    Ji P, Yuan C, Ma S, Fan J, Fu W, Qiao C.
    Bioorg Med Chem; 2016 Dec 01; 24(23):6174-6182. PubMed ID: 27816267
    [Abstract] [Full Text] [Related]

  • 17. Targeting Cell Necroptosis and Apoptosis Induced by Shikonin via Receptor Interacting Protein Kinases in Estrogen Receptor Positive Breast Cancer Cell Line, MCF-7.
    Shahsavari Z, Karami-Tehrani F, Salami S.
    Anticancer Agents Med Chem; 2018 Dec 01; 18(2):245-254. PubMed ID: 28933271
    [Abstract] [Full Text] [Related]

  • 18. 2-Ethoxystypandrone, a novel small-molecule STAT3 signaling inhibitor from Polygonum cuspidatum, inhibits cell growth and induces apoptosis of HCC cells and HCC Cancer stem cells.
    Li W, Zhang Q, Chen K, Sima Z, Liu J, Yu Q, Liu J.
    BMC Complement Altern Med; 2019 Feb 01; 19(1):38. PubMed ID: 30709346
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and evaluation of novel alkannin and shikonin oxime derivatives as potent antitumor agents.
    Wang R, Zhang X, Song H, Zhou S, Li S.
    Bioorg Med Chem Lett; 2014 Sep 01; 24(17):4304-7. PubMed ID: 25127868
    [Abstract] [Full Text] [Related]

  • 20. Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma.
    Page BD, Croucher DC, Li ZH, Haftchenary S, Jimenez-Zepeda VH, Atkinson J, Spagnuolo PA, Wong YL, Colaguori R, Lewis AM, Schimmer AD, Trudel S, Gunning PT.
    J Med Chem; 2013 Sep 26; 56(18):7190-200. PubMed ID: 23968501
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.